Role of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) in denervation-induced atrophy in aged muscle: facts and hypotheses by unknown
Gouspillou et al. Longevity & Healthspan 2013, 2:13
http://www.longevityandhealthspan.com/content/2/1/13REVIEW Open AccessRole of peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α) in
denervation-induced atrophy in aged muscle:
facts and hypotheses
Gilles Gouspillou1,2,5, Martin Picard3,6, Richard Godin4, Yan Burelle4 and Russell T Hepple1,2*Abstract
Aging-related loss of muscle mass, a biological process named sarcopenia, contributes to mobility impairment, falls,
and physical frailty, resulting in an impaired quality of life in older people. In view of the aging of our society,
understanding the underlying mechanisms of sarcopenia is a major health-care imperative. Evidence obtained from
human and rodent studies demonstrates that skeletal muscle denervation/reinnervation cycles occur with aging, and
that progressive failure of myofiber reinnervation is a major cause of the accelerating phase of sarcopenia in advanced
age. However, the mechanisms responsible for the loss of myofiber innervation with aging remain unknown. The two
major strategies that counteract sarcopenia, that is, caloric restriction and endurance training, are well known to
protect neuromuscular junction (NMJ) integrity, albeit through undefined mechanisms. Interestingly, both of these
interventions better preserve PGC-1α expression with aging, a transcriptional coactivator which has recently been
shown to regulate key proteins involved in maintaining NMJ integrity. We therefore propose that the aging-related
decline in PGC-1α may be a central mechanism promoting instability of the NMJ and consequently, aging-related
alterations of myofiber innervation in sarcopenia. Similarly, the promotion of PGC-1α expression by both caloric
restriction and exercise training may be fundamental to their protective benefits for aging muscle by better preserving
NMJ integrity.
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Introduction
One of the most significant changes associated with nor-
mal aging is a progressive loss of muscle mass and
strength, a biological process defined as sarcopenia [1]. In-
deed, sarcopenia is considered as the major factor leading
to mobility impairment, falls, and physical frailty in older
people [2,3], dramatically impairing quality of life of
afflicted individuals. Underscoring the magnitude of
sarcopenia’s impact, in 2002, a study conducted in the
United States revealed that approximately 64% and 31% of* Correspondence: russell.hepple@mcgill.ca
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distribution, and reproduction in any mediummen and women aged 60 and older, respectively, had a
height-normalized muscle mass that was below the lower
boundary of the range seen in a healthy young adult (YA)
population [4]. Further to this point, the health-care costs
attributable to sarcopenia are considerable, where it was
estimated at $18.5 billion dollars for the year of 2002 in
the United States [4]. Since the proportion of individuals
over 60 years old is rising steadily and is expected to reach
22% of the worldwide population in 2050 [5], unraveling
the mechanisms involved in sarcopenia to promote devel-
opment of the most effective therapeutic interventions is
one of the major challenges facing health research.
The etiology of sarcopenia is extremely complex and
continues to be the focus of intensive research. Many
different biological mechanisms are proposed to contrib-
ute to sarcopenia, including a decrease in circulating
levels of anabolic hormones and decrease in the anabolictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mation [8-10], activation of proteolytic pathways and de-
creased protein synthesis [11-13], decline in satellite cell
activation and proliferation [14-16], increased oxidative
damage secondary to mitochondrial reactive oxygen species
(ROS) overproduction, accumulation of mitochondrial dys-
function and activation of mitochondrial-mediated apop-
tosis [17], and alterations in the nervous system [18-20].
The relative contributions of all of these suspects are still
unclear and require further study.
Compelling evidence collected over the last few de-
cades places denervation, a potent inducer of muscle at-
rophy [21], as one of the most significant factors driving
sarcopenia, particularly the selective atrophy of an in-
creasing abundance of muscle fibers in advanced stages
of sarcopenia where the functional consequences are
most likely to have clinical impact [22]. As will be
discussed in detail below, skeletal muscle fibers undergo
progressive cycles of denervation and reinnervation
with aging. In this scenario, muscle atrophy is thought
to accelerate when the rate of denervation outpaces the
rate of reinnervation. Support for this view is derived
from the fact that two of the most efficient strategies to
slow down sarcopenia, that is, endurance training (ET)
and caloric restriction (CR), both positively influence
the integrity of the neuromuscular junction (NMJ) in
aged muscles [23]. However, the mechanism(s) driving
the denervation/reinnervation cycles occurring with
aging, as well as progressive failure in reinnervation, re-
main largely unknown.
In the present perspective paper, we will first briefly re-
view the literature in support of denervation as a primary
cause of aging-related muscle atrophy. We will then dis-
cuss the role that aging-related changes in peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α) expression may have in sparking denervation/
reinnervation cycles and in turn, in precipitating aging
muscle atrophy. To support our hypothesis, recent find-
ings indicating that PGC-1α regulates the expression of
key proteins involved in the maintenance of the NMJ, as
well as the documented effects of CR and ET on muscle
aging and PGC-1α, will be discussed.
Denervation as a primary cause of sarcopenia
Compelling evidence exists that denervation is a central
process in sarcopenia and experimental data supporting
this view shows involvement from the peripheral ner-
vous system all the way to myofibers. Details of this
issue are discussed below.
At the spinal cord level, aging is associated with a
gradual decrease in the motor neuron number. One of
the very first studies that investigated the effect of aging
on motor neuron number in humans was conducted in
the late 1970s by Tomlinson and Irving. By estimating thenumber of motor neurons in the lumbosacral segments
from cadavers of previously healthy individuals, these in-
vestigators reported that there was an average loss of total
motor neurons throughout life of approximately 25%, with
a sizeable fraction of subjects older than 60 years showing
motor neuron counts of only 50% of those in early adult
or middle age [24]. Interestingly, no sign of motor neuron
loss was found up to the age of 60 years. These findings
have been corroborated by many other studies that have
also reported an aging-related reduction in motor unit
(MU) number and/or a reduction in both the number and
diameters of motor axons in human ventral roots [25-28].
Importantly, this aging-related decline in motor neuron
number in humans is also a well-established feature of
neuromuscular aging in rodents [22,23,29,30].
In line with these changes in the spinal cord, the num-
ber of downstream excitable MUs - with an MU defined
as all of the muscle fibers that are innervated by a single
motor neuron - was found to be decreased in aged indi-
viduals using the electrophysiological technique of motor
unit number estimation (MUNE) [31-35]. In addition, sev-
eral studies also reported that aging is associated with en-
largement of MUs in humans [34-36] as well as in rats
[37,38]. This lower number and larger size of MUs in aged
muscles indicate that at least some of the myofibers that
become denervated are reinnervated by axonal sprouting
and expansion of existing MUs [39]. Furthermore, the
characteristic fiber type grouping seen with increasing age
in both humans [18,40-44] and animal models [45-47] is
further evidence of repeating cycles of myofiber denerv-
ation followed by reinnervation through axonal sprouting
from adjacent motor axons.
In addition to alterations in MU number and size, there
are also marked changes at the level of the NMJ in both
aging rodents [23,48-53] and humans [54,55]. Among the
most convincing evidence that NMJs undergo aging-
related deterioration was provided in a study conducted by
Balice-Gordon in the late 1990s [53], in which an in vivo
imaging approach was used, allowing the monitoring of
the same NMJ repeatedly over time in living animals.
Using these elegant techniques, Balice-Gordon observed
that a significant portion of mouse NMJs display a grad-
ual loss of motor terminal branches and dispersal of
postjunctional acetylcholine receptor (AChR) clusters
on myofibers with aging [53], such that the vast major-
ity have undergone significant losses of pre- and post-
synaptic sites in very advanced age (24 to 36 months)
[53]. Many studies supporting these initial findings have
since been conducted. For example, using transgenic
mice in which motor axons were indelibly labeled with
fluorescent proteins and by labeling AChRs with fluo-
rescently tagged α-bungarotoxin, Valdez et al. reported
that at 24 months in mice, around 80% of the NMJs
were fragmented and approximately 15% of the NMJs were
Figure 1 Aging-related changes of the neuromuscular system:
the central role of denervation. To illustrate the main
aging-related changes of the neuromuscular system that identify
denervation as a primary cause of sarcopenia, schematic
representations of adult (A) and aged (B) neuromuscular systems
are presented. Key features of neuromuscular aging, all indicative of
denervation, are highlighted as follow: loss of motor neurons
(normally located in lamina IX of the spinal cord; not represented for
clarity purposes) (1), decrease in both axon number and diameter
(2), fiber type grouping (3), increase in myosin heavy chain
co-expression (4), and appearance of fragmented or denervated
neuromuscular junctions (5). See main text for more details.
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ingly, in a study of Fisher 344 rats that did not yet exhibit
signs of aging muscle atrophy, Deschenes et al. observed
significant remodeling of the NMJ morphology in both so-
leus and plantaris (PL) muscles, although changes seen in
soleus muscle were more modest [48]. On the basis of
these results, Deschenes and colleagues suggested that im-
pairment in the integrity of the NMJ morphology precedes
aging muscle atrophy, and consequently that alterations of
myofiber innervation play a causal role in sarcopenia.
At the myofiber level, strong support in favor of denerv-
ation has accumulated over the last few decades. Indeed,
in elegant glycogen depletion experiments, Ansved and
colleagues demonstrated that fibers belonging to individ-
ual MUs had a much higher probability of being beside
one another with increasing age [37]. In addition, aged
muscles are characterized by high level of myosin heavy
chain (MHC) coexpression (that is, fibers expressing more
than one MHC isoform) [42,45,46,56,57], a phenomenon
thought to arise from aging-related denervation [22,58].
Among the arguments in favor of this interpretation is the
fact that experimental/surgical denervation induces a high
level of MHC coexpression within myofibers [59,60]. In
addition, we recently demonstrated that MHC coexpression
and myofiber atrophy in aged rat muscle are directly linked
to a molecular marker of denervation [22]. Specifically, we
showed that myofibers that expressed the sodium channel
isoform - voltage-sensitive sodium channel 1.5 (Nav1.5) - an
isoform that is only seen in adult muscle following denerv-
ation [61,62] - were on average 35% smaller than the inner-
vated fibers, whereas innervated fibers in aged muscle were
only 7% smaller compared with YA muscle [22]. Most im-
pressively, 90% of the severely atrophied fibers (that is.
cross-sectional area ≤1000 μm2) were positive for Nav1.5,
and more than 70% of the fibers that coexpressed fast and
slow MHC together were positive for Nav1.5. Therefore,
available evidence implicates denervation as the primary
cause of both MHC coexpression and myofiber atrophy in
severely atrophied aging skeletal muscle [22].
Taken together, the experimental findings discussed
above (summarized in Figure 1) converge to indicate that
denervation is a central process leading to sarcopenia, par-
ticularly so when the rate of muscle atrophy accelerates in
very advanced age and is, therefore, most likely to precipi-
tate functional impairment. The question that still remains
is whether cycles of denervation and reinnervation are
myofiber- or motor neuron-driven (or both). Although it
may appear obvious to the reader that these alterations
should arise from the progressive loss of motor neurons,
strong rationale exists for the alternate possibility that the
early changes in MU organization may arise from signals
originating in the myofiber compartment. First, recent data
shows that NMJ deterioration and histological markers of
repeating denervation and reinnervation cycles in agingmuscle occur prior to the loss of motor neurons in the
spinal cord [63]. In addition, it has also been shown in
mice selectively overexpressing the uncoupling protein 1
in skeletal muscle, an alteration which induced patho-
logical uncoupling of mitochondrial oxygen consumption
from adenosine triphosphate (ATP) production, that retro-
grade signals from the myofiber can lead to NMJ deterior-
ation and motor neuron axonal die-back [64]. Further to
these points, a mouse model engineered to overexpress
neurotrypsin, an endogenous protease that cleaves and in-
activates agrin at the NMJ, recapitulates key features seen
in normally aging muscle including fiber type grouping,
fiber loss, MHC coexpression and selective fiber atrophy,
and this occurs without a decline in spinal cord motor
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fore appears reasonable to think that changes at the
myofiber level may be central components in initiating
the aging-related denervation-reinnervation cycles. As
will be discussed in the subsequent sections, recent
findings converge to indicate that aging-related changes
in PGC-1α expression in myofibers may be an import-
ant process triggering the onset and development of
changes in the NMJ with aging.
Protective effects of endurance training and caloric
restriction in aging muscle: a role for PGC-1α
Among the most widely studied strategies to counteract
sarcopenia are ET and CR. Both of these strategies are
known to attenuate the age-related loss of muscle mass
[66-68], as evidenced by higher muscle mass in old CR and
ET animals as compared to old control animals [66,67] and
higher fiber cross-sectional area in ET old humans as com-
pared to old sedentary humans [68]. CR in particular not
only attenuates aging muscle atrophy but also promotes a
remarkable preservation of muscle contractile and meta-
bolic capacities [66,69]. Interestingly, CR was also shown
to attenuate the decline in muscle PGC-1α that occurs
with normal aging. Although the initial interpretation of
the consequences of maintenance of PGC-1α by CR was
that this was preserving mitochondrial protein renewal and
thus, mitochondrial function [69], more recent results sug-
gest an alternate interpretation may apply. Specifically, al-
though PGC-1α is best known for its role in promoting
mitochondrial biogenesis, it also plays a key role in regulat-
ing the expression of several components of the NMJ in
the muscle fiber [70]. As will be detailed below, this role of
PGC-1α suggests the impact of both the decline in muscle
PGC-1α with normal aging and its preservation by CR and
ET may have significant impact on the integrity of the
NMJ with aging.
In an elegant study, Valdez et al. found in mice that
were either calorie restricted or endurance trained there
was superior maintenance of NMJ integrity during aging
[23]. Although a remarkable diversity of mechanisms are
regulated by ET and CR, one of the best characterized
and common effects of both strategies is that they in-
duce an increase in the expression of PGC-1α (see [71]
for an extensive review).Therefore, on the basis of this
fact and the known role of PGC-1α in regulating expres-
sion of key components of the NMJ, we speculate that
CR- and ET-induced increase in PGC-1α mediates the
protective effects of these interventions on the aging
NMJ. Consistent with this view, transgenic mice with
muscle-specific overexpression of PGC-1α exhibit an at-
tenuated degradation of NMJ integrity at an age where
muscle is beginning to show initial signs of aging [52].
These data therefore provide a strong rationale for the
idea that PGC-1α is involved in aging-related alteration ofNMJ stability. Additionally, both mRNA levels [52,69] and
protein content of PGC-1α are known to be reduced in
aging muscle [72,73] (Figure 2A), although this was not
seen in a recent study of aging mice [74]. In summary, be-
cause of the protective influence of PGC-1α overexpression
on NMJ integrity with aging [52], declines in muscle PGC-
1α with aging could lead to impaired integrity of myofiber
innervation, whereas upregulation of PGC-1α with CR and
ET could explain the protection of the NMJ with aging by
these interventions.
PGC-1α in aging-related denervation
Given the fact that PGC-1α is usually considered as the
master regulator of mitochondrial biology [75,76] it is pos-
sible that at least some of its protective effects on muscle
innervation with aging [52] may be mediated by improved
mitochondrial function. Indeed, alterations of different as-
pects of mitochondrial biology, including apoptotic signal-
ing [17], altered energetics [77,78] and increased ROS
production [79], are proposed to contribute to the devel-
opment of sarcopenia. However, a recent comprehensive
analysis of these aspects of mitochondrial function in four
muscles experiencing different degrees of aging-related at-
rophy challenged this notion, as there was no relationship
between degree of atrophy and mitochondrial dysfunction
[80]. Indeed, the nature of the alterations in mitochondrial
function in aging muscle, which included a modest eleva-
tion of ROS and sensitization of the mitochondria to an
apoptotic challenge [80], were strikingly similar to the ef-
fects of surgical denervation on mitochondrial function
[81]. Therefore, as these results suggest that intrinsic
changes in mitochondrial function may not be a primary
defect involved in aging-related atrophy, the prevention of
muscle atrophy seen after ET, CR, or when PGC-1α is
overexpressed, may be independent of PGC-1α’s effect on
mitochondrial function. Further to this point, it is import-
ant to note that controversies about the role played by
PGC-1α in mediating ET-induced mitochondrial biogen-
esis in skeletal muscle exist [82-84].
As mentioned above, recent findings indicate that
PGC-1α is directly involved in regulating the expression of
proteins required to maintain NMJ integrity. Using muscle-
specific PGC-1α knockout and PGC-1α overexpressing
mice, Handschin et al. recently demonstrated that PGC-1α
regulates the expression of key proteins involved in the
maintenance of the NMJ [70], including muscle-specific kin-
ase (MuSK), a tyrosine kinase in muscle that coordinates
signals involved in clustering of AChRs in the postsynaptic
membrane of the NMJ [85]. The decrease in PGC-1α ex-
pression widely reported in aged muscles could thus trigger
NMJ instability that ultimately leads to myofiber denerv-
ation through a decrease in MuSK expression and altered
downstream signaling that is essential to maintaining the
structural organization of the AChRs on the postjunctional
Figure 2 Aging-related changes in PGC-1α and muscle-specific kinase (MuSK). (A) Aging-related changes in PGC-1α expression. Data
adapted from [69] (with permission from Oxford University Press), where PGC-1α expression was determined in gastrocnemius muscle of young
adult (YA; 8 to 10 months) late middle-aged (LMA; 30 months) and senescent (SEN; 35 months) Fisher 344/Brown Norway F1 hybrids rats. Note
the dramatic decrease in muscle PGC-1α expression from adulthood to LMA and its partial recovery from LMA to SEN. (B) Evidence for
aging-related decrease in MuSK content at the neuromuscular junction (NMJ). MuSK protein content at the NMJ was determined in situ by
immunolabeling plantaris cross-sections from YA (6 months) and SEN (35 months) rats with DAPI (labeling nuclei - blue in merge image),
α-bungarotoxin (labeling acetylcholine receptors - green in merge image), and anti-MuSK antibody (kindly provided by Dr. Markus Rüegg; red in
merge image) using protocols we previously described [22,57]. A control slide, for which the incubation with the anti-MuSK antibody was
omitted, is presented at the bottom of panel B. White arrows point toward a NMJ having very low MuSK protein content in SEN muscle. (C)
Aging-related changes in PGC-1α determined in situ. Cross-sections of the white (glycolytic) gastrocnemius region of one YA and SEN rat were
immunolabeled for PGC-1α (green), dystrophin (red) and nuclei (blue) according to methods described in [22]. The anti-PGC-1α antibody was
purchased from Millipore (AB3242; Millipore, Billerica, MA, USA). PGC-1α content was quantified by tracing each fiber using ImageJ (images on the
right). A control slide, for which incubation with the anti-PGC-1α antibody was omitted, is presented at the bottom. The graph on the right
presents PGC-1α content as a function of fiber size. *P <0.05 vs. YA, #P <0.05 vs. small fibers (<1000 μm2). DAPI, 4′,6′-diamidino-2-phénylindole;
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha.
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liminary data suggesting that MuSK protein content at the
level of the NMJ is decreased in the PL muscle of senescent
(SEN) rats as compared to their YA counterparts (Figure 2B).
Also consistent with an important role for a decline inMuSK signaling in causing aging muscle atrophy, a mouse
transgenically modified to overexpress neurotrypsin [65], an
endogenous protease that inactivates neural agrin [86] and
thereby decreases MuSK activity [85], also causes precocious
aging muscle atrophy with hallmark features we see in
Figure 3 PGC-1α in aging-related denervation/reinnervation cycles: a hypothetical mechanism. In adult muscle (1), PGC-1α is known to
regulate expression of proteins involved in neuromuscular junction integrity, such as muscle-specific kinase (MuSK) and three acetylcholine
receptor subunits. We hypothesize that decline in PGC-1α expression with aging (see Figure 2) leads to a decreased expression of MuSK and
acetylcholine receptor subunits (2), therefore promoting neuromuscular instability (3) and subsequent loss of innervation and decrease in fiber
size (4). We also hypothesize that changes in cellular conditions secondary to denervation (namely, an increase in mitochondrial reactive oxygen
species generation) promotes an increase in PGC-1α expression which ultimately, through an increase in the expression of MuSK and
acetylcholine receptor subunits (5), promotes muscle fiber reinnervation and partial recovery of fiber size (6). At advanced stages of aging, the
blunted response of PGC-1α may prevent successful reinnervation and therefore aggravate the decrease in fiber size (5). PGC-1α, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha.
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as a primary cause of sarcopenia”).
How could PGC-1α drive aging-related reinnervation?
As mentioned previously, >90% of the very small fibers
(<1000 μm2) whose accumulation tracks the accelerat-
ing trajectory of whole muscle atrophy with aging [45]
appear to be denervated based upon expression of the
denervation-specific sodium channel, Nav1.5 [22]. Inter-
estingly, these very small fibers contain high levels of pro-
tein carbonyls [87], indicating that these fibers undergo
oxidative stress with aging. In explaining this observa-
tion, experimental denervation increases mitochondrial
ROS production [88], and thus, it is reasonable to ex-
pect mitochondrial ROS generation to increase in thesporadically denervated myofibers seen in aging muscle.
Interestingly, high levels of ROS can increase PGC-1α
expression, either directly or indirectly through adeno-
sine monophosphate-activated protein kinase (AMPK)
activation [89]. Although AMPK hyperactivation can trig-
ger the activation of a muscle atrophy program and has
been suggested as a potential contributor to sarcopenia
[90], we speculate that it might serve as an integrator of
the increased mitochondrial ROS signal in denervated
muscle fibers [88] to increase PGC-1α activity/expression.
In turn, we hypothesize that this would facilitate an in-
crease in MuSK that leads to reconstitution of the post-
synaptic AChR cluster in preparation for reinnervation. In
support of this hypothesis, we previously reported a partial
recovery of PGC-1α expression in SEN rats as compared
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an observation consistent with the high abundance of de-
nervated myofibers at this age [22]. We also found, in a
preliminary study, that in contrast to fibers with normal
size (characterized by a significant decrease in PGC-1α
content), atrophied fibers (<1000 μm2 in cross-sectional
area) display a PGC-1α content similar to that seen in
YA fibers (Figure 2C). Additionally, PGC-1α expression is
upregulated in skeletal muscle of superoxide dismutase
(SOD)−/− mice, an animal model exhibiting both increased
oxidative stress and severe signs of denervation [91,92].
Thus, an increase in PGC-1α expression following aging-
related denervation, followed by an upregulation of MuSK
(see above) and subsequent reaggregation of the postsyn-
aptic AChRs, could explain the reinnervation phenomenon
seen with muscle aging (Figure 3).
Finally, a blunted response of the AMPK/PGC-1α axis
may undermine reinnervation in more advanced aged
muscle. Indeed, the AMPK/PGC-1α axis has been shown
to be less responsive in aged skeletal muscle [93]. In this
context, it is interesting to consider that 5 or 7 months of
ET in rats from middle age to senescence did not increase
muscle PGC-1α content [94], suggesting that the response
of PGC-1α to metabolic stimuli is blunted at advanced
stages of aging. This blunted response of PGC-1α may im-
pair transcriptional activation of NMJ components and
lead to failure in reinnervation. This would explain why at
advanced stages of aging denervation rates surpass
reinnervation rates, leading to a marked accumulation
of small angular denervated myofibers and causing a
marked acceleration of muscle atrophy [22,45].
Conclusions
As emphasized in the present review, data collected over
the last few decades position denervation as a primary
cause of sarcopenia. Here, we present a strong rationale
for proposing that cyclic oscillations in PGC-1α play a
key role in the denervation/reinnervation cycles seen in
aged muscle, through the transcriptional regulation of
key proteins involved in the maintenance of NMJ integ-
rity (Figure 3). On this basis, we argue that further stud-
ies testing this hypothesis will provide a basis for more
broadly understanding the therapeutic potential of PGC-
1α as a countermeasure for sarcopenia [95], as well as
further illuminating the mechanisms of NMJ deterior-
ation in aging muscle. Of particular importance will be
testing the efficacy of PGC-1α at ages where whole muscle
atrophy becomes severe and thus most likely to yield clin-
ical consequence.
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